AR and prostate cancer: Androgens are known drivers of prostate cancer, and inhibition of the androgen receptor (AR) signaling axis remains a mainstay of systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC).